Dear Fellow MPN patients, as someone who has been taking a Curcumin supplement for more than 3 years, I was encouraged to come across this research by Kyoto University published 7 Dec 2022…. Hence relatively new data. There is frequent discussion on this site regarding the benefits of Curcumin and I suspect most are aware of the limitations due to lack of bioavailability and stability, hence the choice of formulation is an important consideration. I personally take Longvida since there is Pharmacokinetic data to support the bioavailability claims, however many other formulations are available. This new research from Kyoto University seems to indicate that a pro-drug approach not only overcomes the bioavailability and stability issues but there is a high conversion rate to Curcumin in the bone marrow…… the very site and source of many of our MPN issues. Still very early days but nonetheless an interesting avenue of research.
“Kanai’s team has found a possible detour around the problem by deductively identifying the enzyme GUSB for its key role in TBP1901 conversion to curcumin. The scientists hypothesized that this conversion would not be observed in mice with genetically impaired GUSB. They also confirmed, using a CRISPR-Cas9 screen method, that curcumin also has essential therapeutic targets.
“The high conversion rate of TBP1901 to curcumin in bone marrow warrants its clinical application for diseases growing in the marrow like multiple myeloma and leukemia,” notes Kanai.
Potential Polycythmia?
Another newly diagnosed
Test Results - good news for now
